smooth muscle Myosin heavy chain 11 Antibody [J22F5]

Catalog No.: F2948

Application: Reactivity: Human

Lane 1: Human testis

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 - 1:10000 IHC1:1000 IF1:50 FCM1:20

Application
WB, IHC, IF, FCM

Source
Rabbit Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
227 kDa 227 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
Smooth muscle Myosin heavy chain 11 Antibody [J22F5] detects endogenous levels of total smooth muscle Myosin heavy chain 11 protein.

Clone
J22F5

Synonym(s)
KIAA0866; MYH11; Myosin-11; Myosin heavy chain 11; SMMHC

Background
Smooth muscle myosin heavy chain 11 (MYH11) is a contractile protein belonging to the myosin II superfamily, forming the primary structural component of thick filaments in smooth muscle cells of blood vessels, gastrointestinal tract, and respiratory system. MYH11 consists of an N-terminal globular head domain containing actin-binding and ATPase sites, a neck region that pivots to amplify movement, and an extended α-helical coiled-coil tail domain that dimerizes with another heavy chain and associates with two pairs of regulatory light chains to form the functional hexameric myosin II molecule. MYH11 converts ATP hydrolysis energy into mechanical force by cyclically binding actin, undergoing a power stroke, and dissociating, enabling smooth muscle contraction regulated by RhoA/ROCK/MLC kinase signaling that phosphorylates myosin light chains to relieve inhibition. MYH11 maintains vascular tone, organ motility, and cytoskeletal integrity, interacting with tropomyosin and caldesmon to modulate actin-myosin dynamics during proliferation and migration. Mutations in MYH11 cause familial thoracic aortic aneurysm/dissection by disrupting contractile apparatus stability, while CBFB-MYH11 fusions characterize a favorable-risk acute myeloid leukemia subtype inv(16); additional associations include megacystis-microcolon-intestinal hypoperistalsis syndrome, patent ductus arteriosus, and visceral myopathies.

Background

Smooth muscle myosin heavy chain 11 (MYH11) is a contractile protein belonging to the myosin II superfamily, forming the primary structural component of thick filaments in smooth muscle cells of blood vessels, gastrointestinal tract, and respiratory system. MYH11 consists of an N-terminal globular head domain containing actin-binding and ATPase sites, a neck region that pivots to amplify movement, and an extended α-helical coiled-coil tail domain that dimerizes with another heavy chain and associates with two pairs of regulatory light chains to form the functional hexameric myosin II molecule. MYH11 converts ATP hydrolysis energy into mechanical force by cyclically binding actin, undergoing a power stroke, and dissociating, enabling smooth muscle contraction regulated by RhoA/ROCK/MLC kinase signaling that phosphorylates myosin light chains to relieve inhibition. MYH11 maintains vascular tone, organ motility, and cytoskeletal integrity, interacting with tropomyosin and caldesmon to modulate actin-myosin dynamics during proliferation and migration. Mutations in MYH11 cause familial thoracic aortic aneurysm/dissection by disrupting contractile apparatus stability, while CBFB-MYH11 fusions characterize a favorable-risk acute myeloid leukemia subtype inv(16); additional associations include megacystis-microcolon-intestinal hypoperistalsis syndrome, patent ductus arteriosus, and visceral myopathies.

References
[1] Kuang SQ, et al. Circ Res. 2012 May 25;110(11):1411-22. [2] Kwartler CS, et al. J Biol Chem. 2014 May 16;289(20):14075-88.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%